UBS analyst Daniel Brennan said his positive investment case on Exact Sciences is unchanged following its Q4 results. The analyst said his sales estimates will remain above consensus and he sees additional levers to help drive upside, including a greater ramp in test utilization, greater doctor additions, penetrating the 45-49 year cohort, and the retest opportunity. Brennan reiterated his Buy rating and $109 price target on Exact Sciences shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.